苦参素抗肝纤维化作用的临床观察

Effects of Marine on Antifibrosis in Patients with Chronic Hepatitis B

目的探讨苦参素在慢性病毒性肝炎抗肝纤维化中的作用。方法选择160例慢性乙型肝炎患者,分为观察组及对照组。观察组在常规治疗基础上给予苦参素6mL肌肉注射,每日1次;对照组常规治疗。分别于治疗前后检测肝功能、病毒指标,用放射免疫法(RIA)测定肝纤维化血清学指标透明质酸(HA)、层黏连蛋白(LM)、III型前胶原(PCIII)、IV型胶原(IV-C)及B超测定门静脉内径(Dpv)。结果观察组治疗后肝纤维化指标均明显下降,HA、LM、PCⅢ、Ⅳ-C分别为(151.42±19.43)ng/mL、(115.75±20.92)ng/mL、(159.60±55.10)ng/mL和(57.60±33.29)ng/mL,与治疗前及对照组治疗后比较差异有统计学意义(P<0.01);Dpv治疗后明显减小(12.8±0.17)cm,与对照组治疗后比较差异亦有统计学意义(P<0.05)。结论苦参素有明显的抗肝纤维化作用,同时还能减轻和缓解门静脉高压症。

Objective To explore the effect of Marine on antifibrosis in patients chronic hepatitis B. Methods 160 patients with chronic hepatitis B（CHB） were divided into two groups： Marrine group （80 patients） and the control group （80 patients）. The levels of serum fibrosis markers were monitored with radioimmunoassay（RIA） and the diameter of portal vein（DPV） was measured by ultrasound B before and after treatment in two groups. Results The serum parameters of fibrosis significantly c ameter of portal vein significantly reduced hanged after 3 months＇ treatment in treated groups（ P 〈 0.01）, and diin treated groups（ P 〈 0.05）. Conclusion Matrine has the effect of antifibrosis and alleviation of portal vein pressure.